BioSante Pharmaceuticals, Inc. Reports Receipt of $2.16 Million in Elestrin(TM) Royalty Buydown With Azur Pharma Inc., and Financial Results for 2009

March 30, 2010 |

1 min read

Twitter
LinkedIn
Facebook
Email
Print

LINCOLNSHIRE, Ill.--(BUSINESS WIRE)--BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced the successful completion of the Azur Pharma Elestrin royalty buydown, and financial results for the year ended December 31, 2009.

Twitter
LinkedIn
Facebook
Email
Print

Alliances